MCID: NNL004
MIFTS: 56

Nonalcoholic Fatty Liver Disease

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Nonalcoholic Fatty Liver Disease

MalaCards integrated aliases for Nonalcoholic Fatty Liver Disease:

Name: Nonalcoholic Fatty Liver Disease 12 26 38 15
Non-Alcoholic Fatty Liver Disease 12 26 17 74
Nonalcoholic Steatohepatitis 26 74
Fatty Liver 26 74
Steatosis 26 17
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 26
Non-Alcoholic Fatty Liver 17
Fatty Degeneration 74
Steatohepatitis 74
Nafld 26
Nash 26

Classifications:



Summaries for Nonalcoholic Fatty Liver Disease

Genetics Home Reference : 26 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

MalaCards based summary : Nonalcoholic Fatty Liver Disease, also known as non-alcoholic fatty liver disease, is related to hepatocellular carcinoma and psoriasis. An important gene associated with Nonalcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Tocopherol and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is is not caused by heavy alcohol use.

Related Diseases for Nonalcoholic Fatty Liver Disease

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Nonalcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 478)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 31.3 MIR122 MIR130A MIR183 MIR200A MIR203A MIR26A1
2 psoriasis 31.2 MIR122 MIR200A MIR203A MIRLET7E
3 breast cancer 30.5 MIR10B MIR122 MIR200A MIR203A MIR34A MIR429
4 leukemia, acute lymphoblastic 30.4 MIR130A MIR203A MIR451A MIRLET7E
5 prostate cancer 30.3 MIR10B MIR183 MIR203A MIR34A MIRLET7D MSR1
6 primary biliary cirrhosis 30.2 MIR122 MIR451A
7 lymphoma, hodgkin, classic 29.9 MIR140 MIR200A
8 muscular dystrophy, duchenne type 29.8 MIR130A MIR34A
9 lung cancer 29.1 MIR130A MIR140 MIR183 MIR200A MIR203A MIR26A1
10 fatty liver disease, nonalcoholic 2 12.4
11 fatty liver disease 12.3
12 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.2
13 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 12.1
14 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.1
15 hypertriglyceridemia, transient infantile 12.0
16 fatty liver disease, nonalcoholic 1 11.9
17 liver disease 11.8
18 reye syndrome 11.6
19 choline deficiency disease 11.3
20 congenital generalized lipodystrophy 11.3
21 visceral steatosis, congenital 11.3
22 corticosteroid-binding globulin deficiency 11.1
23 lipodystrophy, congenital generalized, type 2 11.1
24 lipodystrophy, congenital generalized, type 3 11.1
25 lipodystrophy, familial partial, type 6 11.1
26 fibrosis, neurodegeneration, and cerebral angiomatosis 11.1
27 diabetes mellitus, noninsulin-dependent 11.0
28 nonalcoholic steatohepatitis 11.0
29 neutral lipid storage disease with myopathy 11.0
30 combined oxidative phosphorylation deficiency 16 11.0
31 morbid obesity and spermatogenic failure 11.0
32 mitochondrial dna depletion syndrome 4a 11.0
33 chylomicron retention disease 11.0
34 adrenomyodystrophy 11.0
35 lipodystrophy, congenital generalized, type 1 11.0
36 3-methylglutaconic aciduria, type v 11.0
37 hypermanganesemia with dystonia 1 11.0
38 lipodystrophy, congenital generalized, type 4 11.0
39 lipodystrophy, familial partial, type 5 11.0
40 muscular dystrophy, limb-girdle, autosomal recessive 18 11.0
41 interstitial lung and liver disease 11.0
42 combined oxidative phosphorylation deficiency 21 11.0
43 infantile liver failure syndrome 2 11.0
44 mitochondrial dna depletion syndrome 15 11.0
45 bile acid synthesis defect, congenital, 6 11.0
46 diabetes mellitus 10.9
47 hepatitis 10.8
48 lipid metabolism disorder 10.6
49 polycystic ovary syndrome 10.6
50 sleep apnea 10.6

Graphical network of the top 20 diseases related to Nonalcoholic Fatty Liver Disease:



Diseases related to Nonalcoholic Fatty Liver Disease

Symptoms & Phenotypes for Nonalcoholic Fatty Liver Disease

Drugs & Therapeutics for Nonalcoholic Fatty Liver Disease

Drugs for Nonalcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 373)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Telmisartan Approved, Investigational Phase 4,Phase 1 144701-48-4 65999
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
6
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
7
Insulin glargine Approved Phase 4,Phase 2 160337-95-1
8
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
9
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
10
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
11
Empagliflozin Approved Phase 4,Phase 2,Not Applicable 864070-44-0
12
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
13
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
14
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
15
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
16
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
17
Glucagon Approved Phase 4,Phase 2,Not Applicable 16941-32-5
18
Insulin Detemir Approved Phase 4 169148-63-4 5311023
19
Insulin Aspart Approved Phase 4 116094-23-6 16132418
20
Gliclazide Approved Phase 4 21187-98-4 3475
21
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
22
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
23
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5381226 5458213
24
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2 58-22-0, 481-30-1 10204 6013
25
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
26
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
27
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
28
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
29
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
30
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
31
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 46783403 6436173
32
Glimepiride Approved Phase 4 93479-97-1 3476
33
Phentermine Approved, Illicit Phase 4 122-09-8 4771
34
Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
35
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
36
Alogliptin Approved Phase 4 850649-61-5 11450633
37
Saxagliptin Approved Phase 4 361442-04-8 11243969
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
39
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
40
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
41
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
42
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
43
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 5280795 6221
44
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
45
Ginseng Approved, Investigational, Nutraceutical Phase 4,Not Applicable 50647-08-0
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 59-30-3 6037
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
48 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6829-55-6
49 Ipragliflozin Investigational Phase 4 761423-87-4
50
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0

Interventional clinical trials:

(show top 50) (show all 740)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
5 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
7 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
8 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
9 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
10 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
11 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
12 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
13 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
14 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
15 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
16 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
17 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
18 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
19 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
20 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
21 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
22 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
23 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
24 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
25 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
26 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
27 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
28 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
29 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
30 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
31 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
32 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
33 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4 Metadoxine
34 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
35 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Recruiting NCT03198572 Phase 4 Placebo;Berberine
36 Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery Recruiting NCT03849729 Phase 4 Phentermine
37 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
38 High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes Recruiting NCT03403556 Phase 4 Rosuvamibe;Monorova
39 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease Active, not recruiting NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
40 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Active, not recruiting NCT03222206 Phase 4 Salsalate
41 Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases Not yet recruiting NCT03910361 Phase 4 Evogliptin;Pioglitazone
42 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Not yet recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
43 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
44 Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Not yet recruiting NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
45 Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism Not yet recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
46 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes Not yet recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
47 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
48 Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
49 Fatty Liver Study in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
50 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin

Search NIH Clinical Center for Nonalcoholic Fatty Liver Disease

Genetic Tests for Nonalcoholic Fatty Liver Disease

Anatomical Context for Nonalcoholic Fatty Liver Disease

MalaCards organs/tissues related to Nonalcoholic Fatty Liver Disease:

42
Liver, Testes, Kidney, Bone, Endothelial, Ovary, Prostate

Publications for Nonalcoholic Fatty Liver Disease

Articles related to Nonalcoholic Fatty Liver Disease:

(show top 50) (show all 6598)
# Title Authors Year
1
Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. ( 30805370 )
2019
2
Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. ( 30727943 )
2019
3
Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. ( 30732129 )
2019
4
The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. ( 30791768 )
2019
5
Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. ( 30657626 )
2019
6
Comparative analysis of bile acid spectrum in non-alcoholic fatty liver disease and cholelithiasis. ( 31094171 )
2019
7
Association between non-alcoholic fatty liver disease and colorectal cancer. ( 31092057 )
2019
8
Crohn's Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat Fraction Mapping. ( 30876963 )
2019
9
Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link? ( 31089474 )
2019
10
Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. ( 30993553 )
2019
11
Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. ( 30961499 )
2019
12
Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. ( 30970431 )
2019
13
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. ( 30788048 )
2019
14
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. ( 30734333 )
2019
15
Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. ( 30745809 )
2019
16
Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. ( 30765935 )
2019
17
Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. ( 30428692 )
2019
18
Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. ( 30470912 )
2019
19
Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. ( 30089409 )
2019
20
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( 30682184 )
2019
21
LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in nonalcoholic fatty liver disease. ( 31064820 )
2019
22
Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis. ( 31067493 )
2019
23
Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis. ( 31070259 )
2019
24
Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. ( 31071511 )
2019
25
Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. ( 31074909 )
2019
26
Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway. ( 31076985 )
2019
27
Non-alcoholic fatty liver disease with reduced myocardial FDG uptake is associated with coronary atherosclerosis. ( 31077075 )
2019
28
Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. ( 31077838 )
2019
29
Is liver steatosis diagnostic of non-alcoholic fatty liver disease in patients with hereditary fructose intolerance? ( 31078304 )
2019
30
Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. ( 31078721 )
2019
31
Non-alcoholic fatty liver disease and neurological defects. ( 31080056 )
2019
32
A high-sensitivity C-reactive protein as a new predictor of the course of non-alcoholic fatty liver disease in patients after bariatric surgery. ( 31080231 )
2019
33
Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. ( 31080703 )
2019
34
Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. ( 31081390 )
2019
35
Statins and non-alcoholic fatty liver disease. ( 31081583 )
2019
36
Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease. ( 31082855 )
2019
37
Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. ( 31082856 )
2019
38
Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model. ( 31083413 )
2019
39
Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet. ( 31083505 )
2019
40
Non-alcoholic fatty liver disease. ( 31083812 )
2019
41
Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases. ( 31085337 )
2019
42
Diagnosis and management of non-alcoholic fatty liver disease. ( 31085617 )
2019
43
Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. ( 31086120 )
2019
44
Gene expression and DNA methylation alterations in the glycine N-methyltransferase gene in diet-induced nonalcoholic fatty liver disease-associated carcinogenesis. ( 31086990 )
2019
45
Whole-body vibration for patients with nonalcoholic fatty liver disease: a 6-month prospective study. ( 31087530 )
2019
46
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. ( 31089576 )
2019
47
Understanding Environmental Contaminants' Direct Effects on Non-alcoholic Fatty Liver Disease Progression. ( 31090041 )
2019
48
Hepatoprotective Effect of Seed Coat of Euryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1. ( 31092797 )
2019
49
Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy. ( 31094181 )
2019
50
Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. ( 31094185 )
2019

Variations for Nonalcoholic Fatty Liver Disease

ClinVar genetic disease variations for Nonalcoholic Fatty Liver Disease:

6 (show top 50) (show all 92)
# Gene Variation Type Significance SNP ID Assembly Location
1 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh38 Chromosome 22, 43923800: 43923800
2 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh37 Chromosome 22, 44319680: 44319680
3 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh38 Chromosome 22, 43923801: 43923801
4 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh37 Chromosome 22, 44319681: 44319681
5 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh38 Chromosome 22, 43923868: 43923868
6 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh37 Chromosome 22, 44319748: 44319748
7 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh37 Chromosome 22, 44333145: 44333145
8 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh38 Chromosome 22, 43937265: 43937265
9 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh37 Chromosome 22, 44335858: 44335858
10 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh38 Chromosome 22, 43939978: 43939978
11 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh37 Chromosome 22, 44335885: 44335885
12 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh38 Chromosome 22, 43940005: 43940005
13 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh37 Chromosome 22, 44340667: 44340667
14 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh38 Chromosome 22, 43944787: 43944787
15 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh37 Chromosome 22, 44342156: 44342156
16 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh38 Chromosome 22, 43946276: 43946276
17 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh38 Chromosome 22, 43947073: 43947074
18 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh37 Chromosome 22, 44342174: 44342174
19 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh38 Chromosome 22, 43946294: 43946294
20 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh37 Chromosome 22, 44342281: 44342281
21 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh38 Chromosome 22, 43946401: 43946401
22 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh37 Chromosome 22, 44342333: 44342333
23 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh38 Chromosome 22, 43946453: 43946453
24 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh37 Chromosome 22, 44342953: 44342954
25 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh38 Chromosome 22, 43947271: 43947271
26 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh37 Chromosome 22, 44343151: 44343151
27 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs3083314 GRCh38 Chromosome 22, 43947370: 43947371
28 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs3083314 GRCh37 Chromosome 22, 44343250: 44343251
29 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh38 Chromosome 22, 43947472: 43947472
30 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh37 Chromosome 22, 44343352: 44343352
31 PNPLA3 NM_025225.2(PNPLA3): c.*987_*989dupAAA duplication Uncertain significance rs3083314 GRCh38 Chromosome 22, 43947369: 43947371
32 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh38 Chromosome 22, 43923744: 43923744
33 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh37 Chromosome 22, 44319624: 44319624
34 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh38 Chromosome 22, 43924110: 43924110
35 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh37 Chromosome 22, 44319990: 44319990
36 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh38 Chromosome 22, 43926963: 43926963
37 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh37 Chromosome 22, 44322843: 44322843
38 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh38 Chromosome 22, 43927056: 43927056
39 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh37 Chromosome 22, 44322936: 44322936
40 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh37 Chromosome 22, 44328917: 44328917
41 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh38 Chromosome 22, 43933037: 43933037
42 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh37 Chromosome 22, 44328930: 44328930
43 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh38 Chromosome 22, 43933050: 43933050
44 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh37 Chromosome 22, 44335859: 44335859
45 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh38 Chromosome 22, 43939979: 43939979
46 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh37 Chromosome 22, 44336019: 44336019
47 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh38 Chromosome 22, 43940139: 43940139
48 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh37 Chromosome 22, 44342116: 44342116
49 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh38 Chromosome 22, 43946236: 43946236
50 PNPLA3 NM_025225.2(PNPLA3): c.1419C> T (p.Pro473=) single nucleotide variant Uncertain significance rs376208148 GRCh37 Chromosome 22, 44342235: 44342235

Expression for Nonalcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Nonalcoholic Fatty Liver Disease.

Pathways for Nonalcoholic Fatty Liver Disease

Pathways related to Nonalcoholic Fatty Liver Disease according to KEGG:

38
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 MIR10B MIR122 MIR183 MIR200A MIR203A MIR26A1
2 10.96 MIR203A MIRLET7D
3 10.79 MIR200A MIR429
4 10.4 MIRLET7D MIRLET7E

GO Terms for Nonalcoholic Fatty Liver Disease

Cellular components related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 MIR10B MIR122 MIR130A MIR140 MIR183 MIR26A1
2 micro-ribonucleoprotein complex GO:0035068 9.44 MIR10B MIR122 MIR130A MIR140 MIR183 MIR200A

Biological processes related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.47 MIR10B MIR122 MIR130A MIR140 MIR183 MIR200A
2 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.32 MIR130A MIR26A1
3 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.26 MIR140 MIR34A
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.16 MIR26A1 MIR451A
5 negative regulation of vascular associated smooth muscle cell migration GO:1904753 8.96 MIR140 MIR34A

Molecular functions related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR10B MIR130A MIR140 MIR200A MIR203A MIR26A1
2 RNA polymerase II complex binding GO:0000993 8.96 MIR140 MIR378A

Sources for Nonalcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....